We offer dual-target siRNA drug candidates available for out-licensing, focusing on six core therapeutic areas:
- Metabolic diseases
- Cardiovascular diseases
- Liver diseases
- Kidney diseases
- Infectious diseases
- Pulmonary diseases
Core Advantages of Dual-Target siRNA Platform
- Dual-gene silencing design enables synergistic therapeutic effects with a single administration.
- Optimized delivery system improves tissue uptake in lung, liver, kidney and cardiovascular tissues.
- Fewer injections vs. single-target regimens, improving patient compliance.
- Well-established preclinical efficacy and safety data across all indicated disease fields.
Licensing Scope Available
Exclusive or non-exclusive regional rights can be negotiated, covering clinical development, regulatory registration, manufacturing and commercialization. Flexible deal terms include upfront fees, clinical and sales milestones, plus tiered royalties.
Partner Expectation
We seek global pharmaceutical and biotech partners with relevant clinical development capacity, regulatory expertise and commercial channels to advance these siRNA assets into clinical stages and market launch.
Next Step
Qualified interested parties may contact us to obtain non-confidential deck.
Please contact DrugTimes BD Team by email (BD@drugtimes.cn).
Thank you very much!
发布者：DrugTimes001，转载请首先联系contact@drugtimes.cn获得授权
为好文打赏 支持药时代 共创新未来！ 
